AE
Atkinson Edward Morrow III
内部人交易记录
其他尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Discover the detailed record of transactions filed by Atkinson Edward Morrow III. Insider active across 3 companies, notably 89bio, Inc.. In total, 21 disclosures have been published. Split: 0 buy · 2 sells. Total volume traded: €1.4m. Activity tracked since 1 March 2023. The latest transaction was disclosed on 24 February 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Atkinson Edward Morrow III
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报21 总计
1,627 股@ US$485.1124.5% 占其流量Common StockSEC:0000875320-26-000106:0
4,962 股0Common StockSEC:0000875320-26-000082:0
1,903 股@ US$487.7628.6% 占其流量Common StockSEC:0000875320-26-000060:0
872 股@ US$468.4112.6% 占其流量Common StockSEC:0000875320-26-000038:0
3,934 股0Common StockSEC:0000875320-26-000012:0
2,500 股@ US$434.58100.0% 占其流量Common StockSEC:0000875320-25-000236:0
2,482 股@ US$479.6114.0% 占其流量Common StockSEC:0000875320-25-000127:0
1,656 股@ US$483.289.5% 占其流量Common StockSEC:0000875320-25-000107:0
1,529 股@ US$463.468.4% 占其流量Common StockSEC:0000875320-25-000083:0
6,211 股0Common StockSEC:0000875320-25-000061:0
876 股@ US$467.984.9% 占其流量Common StockSEC:0000875320-25-000037:0
5,132 股0Common StockSEC:0000875320-25-000011:0
6,824 股@ US$481.9637.9% 占其流量Common StockSEC:0000875320-24-000174:0
14,112 股0Common StockSEC:0000875320-24-000144:0
1,654 股@ US$431.798.2% 占其流量Common StockSEC:0000875320-24-000101:0
1,201 股@ US$421.775.8% 占其流量Common StockSEC:0000875320-24-000089:0
1,501 股@ US$424.017.3% 占其流量Common StockSEC:0000875320-24-000070:0
832 股@ US$422.744.0% 占其流量Common StockSEC:0000875320-24-000045:0
2,326 股0Common StockSEC:0000875320-24-000020:0
6,250 股@ US$2.6126.5% 占其流量Common StockSEC:0000950170-23-026422:0
10,000 股@ US$4.4473.5% 占其流量Common StockSEC:0000899243-23-007032:0
About Atkinson Edward Morrow III
Atkinson Edward Morrow III is a declarant linked to Vertex Pharmaceuticals INC / MA and VERTEX PHARMACEUTICALS INC / MA as EVP, Chief Technical Ops. Off., and to 89bio, Inc. as Director. Across 21 filings in total, the most recent sampled filings, from 2023-03-03 to 2026-02-26, show 0 in purchases and 1403811 in sales, with Retenue fiscale as the dominant transaction nature.